ORAMED
PHARMACEUTICALS INC.
Hi-Tech
Park 2/5
PO Box
39098
Jerusalem
91390, Israel
August
30, 2010
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, N.E.
Washington,
D.C. 20549
|
|
Re:
|
Oramed
Pharmaceuticals, Inc.
|
Registration
Statement on Form S-1
File
No. 333-164286
Ladies
and Gentlemen:
Pursuant
to Rule 477 of the Securities Act of 1933, as amended (the “Securities Act”),
Oramed Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities
and Exchange Commission (the “Commission”) consent to the withdrawal, effective
as of the date hereof or at the earliest practicable date hereafter, of the
Company’s Registration Statement on Form S-1, File No. 333-164286, together with
all exhibits and amendments thereto (collectively, the “Registration
Statement”). The Registration Statement is being withdrawn due to the length of
time since its initial filing and its not having become effective in such
time. No securities were sold in connection with the offering
described in the Registration Statement.
Upon
grant of the Commission’s consent, please provide a facsimile copy of the
written order consenting to the withdrawal of the Registration Statements to the
undersigned, facsimile number 972 2 566 0004 and to Eliezer Helfgott, Esq. of
Blank Rome LLP, our counsel, at 917-332-3065.
If you
any questions with respect to this matter, please contact Eliezer Helfgott at
212-885-5431.
|
Very
truly yours,
|
|||
|
Oramed
Pharmaceuticals, Inc.
|
|||
|
By:
|
/s/ Yifat Zommer
|
||
|
Yifat
Zommer
|
|||
|
Chief
Financial Officer
|
|||